A.D. Beadell Investment Counsel’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $743K | Sell |
30,875
-19,421
| -39% | -$508K | 0.48% | 60 |
|
|
2026
Q1 | $1.41M | Sell |
50,296
-600
| -1% | -$16K | 0.9% | 39 |
|
|
2025
Q4 | $1.27M | Hold |
50,896
| – | – | 0.82% | 43 |
|
|
2025
Q3 | $1.3M | Sell |
50,896
-265
| -0.5% | -$6.54K | 0.88% | 40 |
|
|
2025
Q2 | $1.24M | Buy |
51,161
+1,000
| +2% | +$23.3K | 0.95% | 38 |
|
|
2025
Q1 | $1.27M | Buy |
50,161
+2,950
| +6% | +$77.2K | 1.06% | 33 |
|
|
2024
Q4 | $1.25M | Buy |
47,211
+3,375
| +8% | +$91.5K | 1.01% | 35 |
|
|
2024
Q3 | $1.27M | Buy |
43,836
+15,900
| +57% | +$464K | 1.01% | 36 |
|
|
2024
Q2 | $781K | Buy |
27,936
+2,355
| +9% | +$64.8K | 0.65% | 53 |
|
|
2024
Q1 | $709K | Buy |
25,581
+2,550
| +11% | +$70.8K | 0.62% | 50 |
|
|
2023
Q4 | $663K | Buy |
23,031
+13,965
| +154% | +$422K | 0.63% | 50 |
|
|
2023
Q3 | $300K | Hold |
9,066
| – | – | 0.31% | 56 |
|
|
2023
Q2 | $332K | Hold |
9,066
| – | – | 0.32% | 55 |
|
|
2023
Q1 | $369K | Buy |
9,066
+3,728
| +70% | +$161K | 0.34% | 56 |
|
|
2022
Q4 | $273K | Hold |
5,338
| – | – | 0.24% | 61 |
|
|
2022
Q3 | $233K | Hold |
5,338
| – | – | 0.21% | 66 |
|
|
2022
Q2 | $279K | Sell |
5,338
-750
| -12% | -$38.2K | 0.23% | 68 |
|
|
2022
Q1 | $315K | Hold |
6,088
| – | – | 0.21% | 71 |
|
|
2021
Q4 | $359K | Sell |
6,088
-843
| -12% | -$41.8K | 0.22% | 75 |
|
|
2021
Q3 | $298K | Sell |
6,931
-800
| -10% | -$35.4K | 0.19% | 80 |
|
|
2021
Q2 | $302K | Buy |
7,731
+843
| +12% | +$32.8K | 0.19% | 80 |
|
|
2021
Q1 | $249K | Hold |
6,888
| – | – | 0.17% | 81 |
|
|
2020
Q4 | $253K | Sell |
6,888
-372
| -5% | -$13.6K | 0.18% | 78 |
|
|
2020
Q3 | $252K | Sell |
7,260
-211
| -3% | -$7.4K | 0.2% | 71 |
|
|
2020
Q2 | $231K | Hold |
7,471
| – | – | 0.2% | 74 |
|
|
2020
Q1 | $231K | Sell |
7,471
-2,880
| -28% | -$98.1K | 0.25% | 67 |
|
|
2019
Q4 | $384K | Sell |
10,351
-26,488
| -72% | -$943K | 0.32% | 70 |
|
|
2019
Q3 | $1.25M | Sell |
36,839
-3,004
| -8% | -$109K | 1.08% | 35 |
|
|
2019
Q2 | $1.64M | Sell |
39,843
-418
| -1% | -$16.6K | 1.41% | 31 |
|
|
2019
Q1 | $1.62M | Sell |
40,261
-853
| -2% | -$34.2K | 1.44% | 30 |
|
|
2018
Q4 | $1.7M | Sell |
41,114
-3,193
| -7% | -$133K | 1.68% | 20 |
|
|
2018
Q3 | $1.85M | Hold |
44,307
| – | – | 1.56% | 23 |
|
|
2018
Q2 | $1.52M | Sell |
44,307
-3,320
| -7% | -$113K | 1.26% | 29 |
|
|
2018
Q1 | $1.6M | Sell |
47,627
-4,348
| -8% | -$149K | 1.38% | 27 |
|
|
2017
Q4 | $1.79M | Sell |
51,975
-738
| -1% | -$25.2K | 1.47% | 27 |
|
|
2017
Q3 | $1.78M | Sell |
52,713
-6,166
| -10% | -$198K | 1.52% | 23 |
|
|
2017
Q2 | $1.88M | Hold |
58,879
| – | – | 1.52% | 24 |
|
|
2017
Q1 | $1.91M | Sell |
58,879
-867
| -1% | -$27.3K | 1.58% | 22 |
|
|
2016
Q4 | $1.84M | Buy |
59,746
+130
| +0.2% | +$3.97K | 1.58% | 23 |
|
|
2016
Q3 | $1.92M | Sell |
59,616
-501
| -0.8% | -$16.8K | 1.6% | 22 |
|
|
2016
Q2 | $2.01M | Buy |
60,117
+264
| +0.4% | +$8.43K | 1.64% | 20 |
|
|
2016
Q1 | $1.68M | Buy |
59,853
+28,445
| +91% | +$813K | 1.55% | 22 |
|
|
2015
Q4 | $961K | Buy |
+31,408
| New | +$988K | 0.84% | 47 |
|
|
2015
Q3 | – | Sell |
-6,610
| Closed | -$210K | – | 108 |
|
|
2015
Q2 | $210K | Hold |
6,610
| – | – | 0.17% | 103 |
|
|
2015
Q1 | $218K | Sell |
6,610
-235
| -3% | -$7.47K | 0.17% | 101 |
|
|
2014
Q4 | $202K | Buy |
+6,845
| New | +$196K | 0.15% | 102 |
|
|
2014
Q2 | – | Sell |
-6,610
| Closed | -$201K | – | 100 |
|
|
2014
Q1 | $201K | Buy |
+6,610
| New | +$197K | 0.16% | 88 |
|
Other funds holding PFE
A.D. Beadell Investment Counsel's PFE Position: Q2 2026 in Review
A.D. Beadell Investment Counsel reduced its Pfizer (PFE) stake by 39% in Q2 2026, selling an estimated $508K and leaving 30,875 shares worth $743K. The position accounts for 0.48% of the portfolio, ranked #60.
A.D. Beadell Investment Counsel first reported a position in PFE in Q1 2014 and has held it in 47 quarters since. The position peaked at $2.01M in Q2 2016. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- A.D. Beadell Investment Counsel held 30,875 shares of Pfizer worth $743K as of Q2 2026.
- A.D. Beadell Investment Counsel sold 19,421 Pfizer shares in Q2 2026, an estimated $508K.
- Pfizer made up 0.48% of A.D. Beadell Investment Counsel's portfolio in Q2 2026, its #60 holding.
- A.D. Beadell Investment Counsel first reported a position in Pfizer in Q1 2014 and has held it in 47 quarters since.
- A.D. Beadell Investment Counsel's Pfizer position peaked at $2.01M in Q2 2016.
- 2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on A.D. Beadell Investment Counsel's 13F filing for Q2 2026, filed 15 Jul 2026.